Replimune Group enters its May 15 earnings report in one of the most electrically charged setups in the biotech space right now: a 43% weekly surge, a third of the float still sold short, and call buyers running the options market.
The short squeeze narrative is hard to ignore. Short interest climbed about 11% over the past week, reaching roughly 34% of the free float — a position that has been building steadily since early April, when it stood near 27%. Shorts added aggressively as the stock recovered from its post-downgrade lows, and now those positions face serious pressure. The stock gained 9.4% on Tuesday alone, closing at $4.09, and the week-on-week move of 42.5% represents one of the sharpest reversals the stock has seen in months. Borrow costs remain surprisingly loose at 0.46% — barely moved despite the pile-up — which means the lending market is not yet reflecting any kind of panic among short holders. Availability remains comfortable enough to open new positions, but the price action tells a different story.
Options traders are leaning decisively into the move. The put/call ratio has dropped to 0.23, well below its 20-day average of 0.32 and close to the annual low of 0.16. That means call volumes are overwhelming puts by a wide margin — a clear reflection of speculative positioning ahead of Thursday's print. This is not defensive hedging. It is directional enthusiasm, and the z-score of -0.93 confirms the skew is meaningful relative to recent history.
The Street, however, is far less enthusiastic. On April 13, the company absorbed a coordinated wave of downgrades. JP Morgan moved to Underweight. Jefferies cut from Buy to Hold, slashing its target from $13 to $2. Leerink dropped from Outperform to Market Perform with a $2 target, down from $11. Wedbush fell from Outperform to Neutral with a $2 target against a prior $19. HC Wainwright went all the way to Sell. Cantor stepped back to Neutral. That April 13 consensus reset — six firms downgrading on the same day — left the mean price target near $3.50. With the stock now above $4, it technically trades through the Street consensus. The bear case is pointed: RP1's overall response rate disappointed, the FDA raised trial-design concerns for the ongoing Phase 3 study, and cash constraints limit room for error. The EPS momentum 30-day score is the strongest data point on the other side, ranking in the 91st percentile, though the 90-day reading at 11 shows that momentum is recent and narrow.
The earnings history offers some encouragement for those holding long. The last two confirmed prints produced next-day gains of 12.2% and 0.4% respectively, with five-day moves of 15% and 11.8%. The prior two showed a mix — one small decline on the day, one small gain — both followed by positive five-day drifts. That pattern of generally positive post-earnings price action into the week following the release has given bulls reason to hold through the event, even if the one-day reaction has been inconsistent.
Baker Bros. Advisors, the largest holder with a 13.4% stake, has not moved its position since December. RTW Investments added over 744,000 shares in the same period. Fidelity built a notably large position, adding over 1.6 million shares as recently as April. These are active biotech specialists choosing to hold or add into a structurally difficult situation — a data point worth noting as the print approaches. Insider activity has been exclusively on the sell side, with the CEO trimming in December and the CCO again in early April, though all at prices well above current levels and at volumes that look more like routine plan-driven sales than meaningful conviction shifts.
Thursday's earnings release is the defining event: what management says about cash runway, any regulatory update on the Phase 3 trial design, and whether the RP1 data evolves in any direction will either validate the week's short squeeze or reset it sharply lower.
See the live data behind this article on ORTEX.
Open REPL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
